中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

74 records (took 0.02 seconds)

    52.
    发明专利
    未知

    公开(公告)号：BRPI0621027A2

    公开(公告)日：2011-11-29

    申请号：BRPI0621027

    申请日：2006-12-28

    Applicant: PHARMACYCLICS INC

    Inventor： JANKOWSKI ORION D ,  PALMER JAMES T ,  HONIGBERG LEE

    IPC: C07D471/06 ,  A61K31/416 ,  A61K31/4375 ,  A61K31/675

    Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.

    53.
    发明专利
    未知

    公开(公告)号：AT531263T

    公开(公告)日：2011-11-15

    申请号：AT10155834

    申请日：2006-12-28

    Applicant: PHARMACYCLICS INC

    Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

    IPC: A01N43/90 ,  A61K31/519 ,  A61P35/00 ,  C07D487/04

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    Pyrimidinopyrazole derivatives as inhibitors of Bruton's tyrosine kinase
    54.
    发明专利
    Pyrimidinopyrazole derivatives as inhibitors of Bruton's tyrosine kinase 未知

    公开(公告)号：NZ575650A

    公开(公告)日：2011-10-28

    申请号：NZ57565006

    申请日：2006-12-28

    Applicant: PHARMACYCLICS INC

    Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

    IPC: A01N43/90 ,  A61K31/519

    Abstract: Disclosed are pyrazolo-pyrimidin derivatives of formula (D) that form covalent bonds with Bruton's tyrosine kinase (Btk), wherein the variables shown in the structure of formula (D) are as defined in the specification. Also described are irreversible inhibitors of Btk; methods for the preparation of these compounds; and pharmaceutical compositions that include the compounds. These Btk inhibitors are suitable for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    55.
    发明专利
    未知

    公开(公告)号：BRPI0622277A2

    公开(公告)日：2011-08-09

    申请号：BRPI0622277

    申请日：2006-12-28

    Applicant: PHARMACYCLICS INC

    Inventor： HONIGBERG LEE ,  VERNER ERIK ,  PAN ZHENGYING

    IPC: A61K31/519 ,  A61P37/00 ,  C07D487/00 ,  C07D487/04

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

    Inhibitors of Bruton's tyrosine kinase
    58.
    发明专利
    Inhibitors of Bruton's tyrosine kinase 未知

    公开(公告)号：AU2010201052A1

    公开(公告)日：2010-04-08

    申请号：AU2010201052

    申请日：2010-03-18

    Applicant: PHARMACYCLICS INC

    Inventor： HONIGBERG LEE ,  PAN ZHENGYING ,  VERNER ERIK

    IPC: C07D471/04 ,  A01N43/90 ,  A61K31/519 ,  A61K31/52 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02

    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Patent Agency Ranking